Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$10.72 USD
+0.07 (0.66%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $10.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ROIV 10.72 +0.07(0.66%)
Will ROIV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stock Market News for Nov 14, 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
Other News for ROIV
Buy Rating on Roivant Sciences Amid Anticipation of High-Potential Phase 2 Asset Reveal
Tracking Baker Brothers Portfolio - Q1 2024 Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), Replimune Group (REPL) and Roivant Sciences (ROIV)
The 'Undercovered' Dozen From June 1-6
Roivant Sciences: Executing On Huge Buyback Program With More To Come